ArriVent BioPharma/$AVBP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ticker
$AVBP
Sector
Primary listing
Employees
52
Headquarters
Website
AVBP Metrics
BasicAdvanced
$800M
-
-$4.02
-
-
Price and volume
Market cap
$800M
52-week high
$34.51
52-week low
$15.47
Average daily volume
301K
Financial strength
Current ratio
12.739
Quick ratio
12.029
Total debt to equity
0.039
Profitability
Management effectiveness
Return on assets (TTM)
-23.41%
Return on equity (TTM)
-50.06%
Valuation
Price to book
2.96
Price to tangible book (TTM)
2.96
Price to free cash flow (TTM)
-5.301
Free cash flow yield (TTM)
-18.86%
Free cash flow per share (TTM)
-3.718
Growth
Earnings per share change (TTM)
-14.41%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
Bulls say / Bears say
Phase 1b FURTHER data showed a 16.0-month median progression-free survival, 53% overall response rate, and 41% confirmed complete response in CNS evaluable EGFR PACC mutant NSCLC patients, supporting the launch of the global pivotal ALPACCA Phase 3 study in the second half of 2025
Completion of a $75 million public offering, backed by joint book-runners Goldman Sachs, Citigroup and Guggenheim, provides critical funding to advance firmonertinib and next-generation ADC programs through key clinical milestones
Coverage initiation by Guggenheim with a buy rating and $45 price target, alongside an average analyst target of $39.40, points to strong institutional confidence in ArriVent’s clinical pipeline upside
Shares down approximately 22% year-to-date reflect investor skepticism around ArriVent’s long clinical timelines and lack of approved products
Announcement of a $75 million equity offering drove a 4.7% post-market share decline, underscoring dilution concerns among shareholders
Analyst sentiment is mixed: only 4 of 8 covering firms rate the stock as buy/strong-buy, with the remainder at hold and a median $40 price target, suggesting limited near-term upside from current levels
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
AVBP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ArriVent BioPharma stock?
ArriVent BioPharma (AVBP) has a market cap of $800M as of September 15, 2025.
What is the P/E ratio for ArriVent BioPharma stock?
The price to earnings (P/E) ratio for ArriVent BioPharma (AVBP) stock is 0 as of September 15, 2025.
Does ArriVent BioPharma stock pay dividends?
No, ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next ArriVent BioPharma dividend payment date?
ArriVent BioPharma (AVBP) stock does not pay dividends to its shareholders.
What is the beta indicator for ArriVent BioPharma?
ArriVent BioPharma (AVBP) does not currently have a Beta indicator.